NDASUBCUTANEOUSSOLUTION
Approved
May 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
BREKIYA (AUTOINJECTOR) (dihydroergotamine mesylate) by Baxter International is 5-ht 1dα and 5-ht 1dβ receptors. First approved in 2025.
Drug data last refreshed 3h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREKIYA is a subcutaneous autoinjector formulation of dihydroergotamine mesylate, a selective 5-HT1D receptor agonist approved for acute migraine treatment. The drug works by constricting intracranial blood vessels and inhibiting neuropeptide release, providing rapid symptom relief during migraine episodes. This represents a modernized delivery format for an established migraine therapeutic class.
Growth12.9 years to LOE
Recent 2025 approval positions BREKIYA in early growth phase with opportunity for commercial team expansion to establish market presence in competitive acute migraine segment.
Mechanism of Action
5-HT 1Dα and 5-HT 1Dβ receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effects at 5-HT 1D receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Started Mar 2010
24 enrolled
Healthy
Career Relevance
BREKIYA represents a growth-stage commercial opportunity for pharma professionals in sales, marketing, and market access, with demand expected to grow as market penetration accelerates through 2030. Career progression is supported by 12.9 years of patent protection, enabling long-term team stability and product line development initiatives.
Brand Manager
Worked on BREKIYA (AUTOINJECTOR) at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.